DrugDashboards

Meropenem

Meropenem · MEROPENEM 1 g/30mL · Injection · Intravenous · Sandoz Inc

NDC 00781-3098-95 · 10 VIAL in 1 CARTON / 30 mL in 1 VIAL · ANDA · View full market →

The short version

10 companies supply this market — deep enough that no single failure threatens the supply. The price is down 12% over the past year, to $4.67 per unit. Put together: this looks like a healthy supply — the boring kind, which is exactly what you want. Historically, drugs in this position went on to a new shortage within 90 days about 0.4% of the time — roughly 3× the typical drug (0.1%).

The numbers behind every sentence are on this page below — and the Watch button emails you when any of them move.

One drug, every price

The same NDC has different prices depending on who is paying. Units differ between rungs — compare within a rung over time, not rung against rung, unless the units match.

ⓘ How this was built
Data sources
  • CMS NADAC (pharmacy acquisition, weekly)
  • CMS Part B ASP quarterly payment limits
  • CMS Maximum Fair Prices (IRA negotiated, NDC-level)
  • Medicare Part D Spending by Drug (data.cms.gov, name-matched)
  • VA FSS / Big4 federal contract prices (va.gov, twice monthly)
  • ACA Federal Upper Limits + weighted AMP (data.medicaid.gov, monthly)
  • California SB-17 WAC filings (list price, per package)
Method

Each rung is the newest figure for this NDC from one federal price system, shown with its own unit. Part D is matched by drug name because CMS publishes no NDCs there; it is gross spending, before confidential rebates.

Pipeline and calculations built by Claude (Fable 5) from the public datasets above. Educational only — verify against primary sources before acting.

  • Pharmacies pay (NADAC)$4.67per EAinvoice-surveyed acquisition cost · Aug 19, 2026
  • Medicare Part B pays (ASP+6%)$0.3250per billing unit (100 MG)HCPCS J2185 · Jul 1, 2026
  • Part D plans paid (avg)$4.31per dosage unitgross, before rebates — matched by drug name · 2024
  • Federal contracts pay (FSS)$47.80per unitGolden State Medical Supply, Inc. · Oct 15, 20241024% of what pharmacies pay — higher than 95% of drugs with this benchmark

Medicare Part D

No Medicare Part D plan in CMS's quarterly files lists this product. That usually means it is discontinued, a repackager's listing, or a product no plan has added to its formulary.

How Part D pricing works →

NADAC price per unit

$0$5.00$10.00Apr 2024Sep 2026$4.67
30 price points · per EASource: CMS NADAC

Estimated fill cost

WAC per package, as filed
$110.00
Reported to Texas DSHS · 2026 annual filing · Sandoz

Manufacturer list price as filed — not what pharmacies actually pay after discounts.

Medicare Part B (ASP)

Payment limit per 100 MG
$0.325
HCPCS J2185 · Jul 1, 2026 quarter · typically ASP + 6%

Medicaid spend (2025)

$890,891
5,165 prescriptions paid by Medicaid nationally · all Medicaid spend →

Supply fragility

10Low risk

Some pressure is visible, but not much — here’s everything the score found to count.

  • sterile injectable+10

The score counts pressure that is already visible — fewer makers, shortages, recalls, falling prices. 0 means none of it; 100 means all of it at once. Recomputed daily · as of Sep 3, 2026

90-day shortage risk (model v2)

0.4%chance of a new FDA shortage posting for meropenem (injectable) in the next 90 days

sterile injectable · OAI inspection at a producing facility (24 months) · sole-source market

For scale: the typical drug’s chance is about 0.1% — this one is 3× that.

Backtested statistical model over the whole market, not this package alone. Model details →

Is this a "specialty" drug?

There's no legal definition — it meets 1 of 6 public criteria. Why that matters →

  • Part D specialty tier
  • Costs ≥ $950/fill · avg $185.36 per prescription
  • Biologic (BLA)
  • Injectable / infused
  • Orphan-drug exclusivity
  • REMS program

Regulatory

Application
ANDA206086
TE code
AP
Approval date
Apr 19, 2016
Patents / exclusivity
None on file

Shortage history

No FDA shortage reports for this drug or its presentations.

Recalls (this NDC)

No enforcement reports list this package NDC.

Manufacturers of Meropenem (Injection)

LabelerStrengthFirst seenLast seen
Armas Pharmaceuticals IncMEROPENEM 1 g/20mLJul 15, 2026Sep 2, 2026
Armas Pharmaceuticals IncMEROPENEM 500 mg/20mLJul 15, 2026Sep 2, 2026
Brooks Steriscience LimitedMEROPENEM 500 mg/20mLJul 15, 2026Sep 2, 2026
Brooks Steriscience LimitedMEROPENEM 1 g/20mLJul 15, 2026Sep 2, 2026
Brooks Steriscience LimitedMEROPENEM ANHYDROUS 2 g/1Jul 15, 2026Sep 2, 2026
Civica, IncMEROPENEM 1 g/30mLJul 15, 2026Sep 2, 2026
Civica, IncMEROPENEM 500 mg/20mLJul 15, 2026Sep 2, 2026
Civica, Inc.MEROPENEM 500 mg/20mLJul 15, 2026Sep 2, 2026
Civica, Inc.MEROPENEM 1 g/20mLJul 15, 2026Sep 2, 2026
Gland Pharma LimitedMEROPENEM 1 g/30mLJul 15, 2026Sep 2, 2026
Gland Pharma LimitedMEROPENEM 500 mg/20mLJul 15, 2026Sep 2, 2026
Hikma Pharmaceuticals USA Inc.MEROPENEM 1 g/30mLJul 15, 2026Sep 2, 2026
Hikma Pharmaceuticals USA Inc.MEROPENEM 500 mg/20mLJul 15, 2026Sep 2, 2026
Mylan Institutional LLCMEROPENEM ANHYDROUS 2 g/1Jul 15, 2026Sep 2, 2026
Qilu Antibiotics Pharmaceutical Co., Ltd.MEROPENEM 1 g/30mLJul 15, 2026Sep 2, 2026
Qilu Antibiotics Pharmaceutical Co., Ltd.MEROPENEM 500 mg/20mLJul 15, 2026Sep 2, 2026
Sandoz IncMEROPENEM 1 g/30mLJul 15, 2026Sep 2, 2026
Sandoz IncMEROPENEM 500 mg/20mLJul 15, 2026Sep 2, 2026
Savior Lifetec CorporationMEROPENEM 500 mg/20mLJul 15, 2026Sep 2, 2026
Savior Lifetec CorporationMEROPENEM 1 g/30mLJul 15, 2026Sep 2, 2026

Roster from daily NDC Directory diffs — first/last seen dates start July 2026.

Cite this page

DrugDashboards, "Meropenem — NDC 00781-3098-95," retrieved September 3, 2026, https://drugdashboards.com/drug/00781309895.

Free to cite with attribution — see how the data is put together.